Skip to content
Back to WHWK

Whitehawk Therapeutics, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
14
Purchases
0
Sales
14
Purchase value
$0.00
Sale value
$2.58M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Scott M. GiacobelloCHIEF FINANCIAL OFFICER
4
Filed Apr 17, 2026Period of report Apr 15, 20260001754154-26-000010
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 16, 2026
Common StockF1141,600$4.13$584.81K295,224Direct
SaleApr 15, 2026
Common StockF1F277,000$3.86$297.22K436,824Direct
Filing footnotes · 2
  1. F1Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
  2. F2Includes an aggregate of 11,822 shares of Common Stock acquired between November 14, 2022 and November 15, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.
Open on SEC EDGAR
Bryan BallSee remarks
4
Filed Apr 15, 2026Period of report Apr 13, 20260001766522-26-000011
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 14, 2026
Common StockF192,460$3.64$336.55K397,106Direct
SaleApr 13, 2026
Common StockF126,389$3.46$91.31K489,566Direct
Filing footnotes · 1
  1. F1Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Open on SEC EDGAR
Bryan BallSee remarks
4
Filed Apr 13, 2026Period of report Apr 9, 20260001766522-26-000009
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 10, 2026
Common StockF16,596$3.43$22.62K515,955Direct
SaleApr 9, 2026
Common StockF150,000$3.57$178.50K522,551Direct
Filing footnotes · 1
  1. F1Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Open on SEC EDGAR
David James LennonDirector · CHIEF EXECUTIVE OFFICER
4
Filed Apr 10, 2026Period of report Apr 9, 20260001995275-26-000012
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 9, 2026
Common StockF114,500$3.38$49.01K518,622Direct
Filing footnotes · 1
  1. F1Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Open on SEC EDGAR
David James LennonDirector · CHIEF EXECUTIVE OFFICER
4
Filed Apr 8, 2026Period of report Apr 6, 20260001995275-26-000008
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 8, 2026
Common StockF163,945$3.40$217.41K533,122Direct
SaleApr 7, 2026
Common StockF194,087$3.43$322.72K597,067Direct
SaleApr 6, 2026
Common StockF1102,395$3.51$359.41K691,154Direct
Filing footnotes · 1
  1. F1Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Open on SEC EDGAR
David James LennonDirector · CHIEF EXECUTIVE OFFICER
4
Filed Apr 3, 2026Period of report Apr 1, 20260001995275-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 2, 2026
Common StockF226,858$3.48$93.47K793,549Direct
Filing footnotes · 4
  1. F1Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
  2. F2Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
  3. F3Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025.
  4. F4Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2026.
Open on SEC EDGAR
David James LennonDirector · CHIEF EXECUTIVE OFFICER
4
Filed Mar 10, 2026Period of report Mar 1, 20260001995275-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 2, 2026
Common StockF25,100$3.3096$16.88K44,579Direct
Filing footnotes · 3
  1. F1Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
  2. F2Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
  3. F3Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024.
Open on SEC EDGAR
Bryan BallSee remarks
4
Filed Mar 10, 2026Period of report Mar 1, 20260001766522-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 2, 2026
Common StockF21,834$3.3096$6.07K206,019Direct
Filing footnotes · 3
  1. F1Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
  2. F2Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
  3. F3Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024.
Open on SEC EDGAR
Scott M. GiacobelloCHIEF FINANCIAL OFFICER
4
Filed Mar 10, 2026Period of report Mar 1, 20260001754154-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 2, 2026
Common StockF22,594$3.3096$8.59K28,100Direct
Filing footnotes · 3
  1. F1Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
  2. F2Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
  3. F3Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.